Department of Hematology, Institute of Hematology and Oncology, Hospital Clínic, Barcelona, Spain.
EBMT LWP Paris Office Hopital Saint-Antoine, Paris, France.
Leuk Lymphoma. 2020 Dec;61(12):2915-2922. doi: 10.1080/10428194.2020.1789624. Epub 2020 Jul 11.
The purpose of this study was to analyze the results of second autologous hematopoietic stem cell transplantation (ASCT2) for patients with relapsed/refractory Hodgkin lymphoma (HL) after a first transplantation (ASCT1). Outcomes for 56 patients receiving an ASCT2 registered in the EBMT database were analyzed. The 4-year cumulative incidences of non-relapse mortality and disease relapse/progression were 5% and 67%, respectively. The 4-year overall survival (OS) and progression-free survival (PFS) were 62% and 28%. In univariate analysis, relapse of HL within 12 months of ASCT1 was associated with a worse OS (35% versus 76%, = 0.01) and PFS (19% versus 29%, = 0.059). Chemosensitivity at ASCT2 predicted better outcomes (4-year OS 72% versus 29%, = 0.002; PFS 31% versus 12%, = 0.015). This series shows that ASCT2 is a safe procedure and a relatively effective option for patients with late relapses after ASCT1 and with chemosensitive disease who are not eligible for an allogeneic transplant.
本研究旨在分析首次自体造血干细胞移植（ASCT1）后复发/难治性霍奇金淋巴瘤（HL）患者进行第二次自体造血干细胞移植（ASCT2）的结果。分析了在 EBMT 数据库中登记的 56 例接受 ASCT2 的患者的结果。4 年无复发生存率和疾病复发/进展的累积发生率分别为 5%和 67%。4 年总生存率（OS）和无进展生存率（PFS）分别为 62%和 28%。单因素分析显示，ASCT1 后 12 个月内 HL 复发与较差的 OS（35%比 76%，=0.01）和 PFS（19%比 29%，=0.059）相关。ASCT2 时的化疗敏感性预测更好的结局（4 年 OS 72%比 29%，=0.002；PFS 31%比 12%，=0.015）。本系列研究表明，ASCT2 是一种安全的治疗方法，对于 ASCT1 后晚期复发且不适合异体移植的化疗敏感患者是一种相对有效的选择。
